Institution
Arizona Heart Institute
Healthcare•Phoenix, Arizona, United States•
About: Arizona Heart Institute is a healthcare organization based out in Phoenix, Arizona, United States. It is known for research contribution in the topics: Stent & Angioplasty. The organization has 215 authors who have published 348 publications receiving 23059 citations.
Topics: Stent, Angioplasty, Aneurysm, Thoracic aorta, Aortic aneurysm
Papers published on a yearly basis
Papers
More filters
Thomas Jefferson University1, Harvard University2, Scripps Health3, University of Pittsburgh4, University of British Columbia5, Memorial Hospital of South Bend6, Yale University7, Arizona Heart Institute8, University of Toronto9, St Lukes Episcopal Hospital10, Johns Hopkins University11, Lenox Hill Hospital12, University of Pennsylvania13, University of Texas at San Antonio14, Cleveland Clinic15
TL;DR: In selected patients, placement of an intracoronary stent, as compared with balloon angioplasty, results in an improved rate of procedural success, a lower rate of angiographically detected restenosis, a similar rate of clinical events after six months, and a less frequent need for revascularization of the original coronary lesion.
Abstract: Background Coronary-stent placement is a new technique in which a balloon-expandable, stainless-steel, slotted tube is implanted at the site of a coronary stenosis. The purpose of this study was to compare the effects of stent placement and standard balloon angioplasty on angiographically detected restenosis and clinical outcomes. Methods We randomly assigned 410 patients with symptomatic coronary disease to elective placement of a Palmaz-Schatz stent or to standard balloon angioplasty. Coronary angiography was performed at base line, immediately after the procedure, and six months later. Results The patients who underwent stenting had a higher rate of procedural success than those who underwent standard balloon angioplasty (96.1 percent vs. 89.6 percent, P = 0.011), a larger immediate increase in the diameter of the lumen (1.72 ±0.46 vs. 1.23 ±0.48 mm, P<0.001), and a larger luminal diameter immediately after the procedure (2.49 ±0.43 vs. 1.99 ±0.47 mm, P<0.001). At six months, the patients with stented ...
4,300 citations
TL;DR: In this prospective multicenter trial of chest pain patients without known CAD, 64-multidetector row CCTA possesses high diagnostic accuracy for detection of obstructive coronary stenosis at both thresholds of 50% and 70% stenosis.
1,941 citations
TL;DR: This trial provides pivotal safety and provisional efficacy data for an allogeneic bone marrow-derived stem cell in post-infarction patients and indicates intravenousAllogeneic hMSCs are safe in patients after acute MI.
1,277 citations
Missouri Baptist Medical Center1, Stanford University2, University of Pennsylvania3, Baylor College of Medicine4, University of Maryland, Baltimore5, University of Duisburg-Essen6, Yale University7, University of Pittsburgh8, Cleveland Clinic9, University of Rostock10, University of Texas Health Science Center at Houston11, University of California, Los Angeles12, Washington University in St. Louis13, Mayo Clinic14, Arizona Heart Institute15
TL;DR: The natural history of aortic disease, indications for repair, outcomes after conventional open surgery, currently available devices, and insights from outcomes of randomized studies using stent-grafts for abdominal aorti aneurysm surgery are reviewed; a suggestion for treatment is offered.
828 citations
Icahn School of Medicine at Mount Sinai1, Columbia University2, Henry Ford Health System3, Baylor College of Medicine4, University of Medicine and Dentistry of New Jersey5, University of North Carolina at Chapel Hill6, Ohio State University7, Arizona Heart Institute8, MedStar Washington Hospital Center9, GlaxoSmithKline10
TL;DR: Patients with New York Heart Association class II or III heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor were studied.
Abstract: Background. Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is often the case in current practice. Methods. We studied 178 patients with New York Heart Association class II or III heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor (captopril or enalapril). The patients were randomly assigned in a double-blind fashion either to continue receiving digoxin (85 patients) or to be switched to placebo (93 patients) for 12 weeks
672 citations
Authors
Showing all 215 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Stephen G. Ellis | 127 | 655 | 65073 |
| Michael R. Jaff | 82 | 442 | 28891 |
| Jürgen Meyer | 57 | 235 | 11865 |
| Christopher P. Appleton | 50 | 108 | 27827 |
| Edward B. Diethrich | 48 | 244 | 8735 |
| Richard A. Schatz | 42 | 106 | 12928 |
| Sheldon Goldberg | 42 | 141 | 12000 |
| Andrew W. Gardner | 42 | 83 | 7320 |
| Gerald Dorros | 41 | 129 | 7630 |
| Hani Shennib | 40 | 108 | 6132 |
| Raimund Erbel | 39 | 194 | 5450 |
| Boris Yoffe | 30 | 103 | 3369 |
| Alexander Kulik | 30 | 86 | 3057 |
| Venkatesh G. Ramaiah | 29 | 80 | 2834 |
| Richard R. Heuser | 28 | 121 | 8946 |